Onconic Therapeutics has secured U.S. patent protection covering the crystal structure and manufacturing method for its anticancer candidate nesuparib, extending intellectual-property coverage through May 2042 beyond the existing compound patent that runs through 2036. The company said on the 31st it had completed payment of U.S. registration fees, while final issuance steps, including assignment of a patent number by the USPTO (U.S. patent authority), are under way. The protected structure is designed to support high-purity, high-stability production, factors that affect quality consistency, reproducibility, regulatory approval and commercial manufacturing. The technology has been filed in more than 30 countries, with registrations completed in South Korea, Japan, Australia, Saudi Arabia and Chile. Nesuparib is a dual-target drug candidate that inhibits Tankyrase and PARP, using synthetic lethality (blocking two cancer-survival pathways). It is in Phase 2 trials for pancreatic, ovarian, endometrial and gastric cancers, with combination studies alongside MSD’s Keytruda and Celltrion’s Vegzelma. Onconic is preparing U.S. development, has received three FDA orphan drug designations, and is holding pre-IND meetings while targeting submission of a U.S. Phase 2 IND application by the end of this year.